All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Peptide-drug conjugates aim to transport inactive anti-tumor agent to malignant cells, which is then cleaved to an active cytotoxic drug. Such approach minimizes effect on healthy cells and leads to reduced adverse side effects. The peptide-drug conjugates consist of the tumor-homing peptide, the cytotoxic agent, and the biodegradable connecting linker.